Bio-Techne (TECH) EBITDA (2009 - 2026)

Bio-Techne's EBITDA history runs 18 years deep, the most recent figure standing at $75.5 million for Q1 2026.

• On a quarterly basis, EBITDA rose 95.04% year-over-year to $75.5 million in Q1 2026; TTM through Mar 2026 was $153.8 million, a 10.58% decrease from a year earlier, with the FY2025 full-year figure at $102.3 million, down 50.53% from the prior year.
• EBITDA climbed to $75.5 million in Q1 2026 per TECH's latest filing, from $54.5 million in the prior quarter.
• Across five years, EBITDA topped out at $94.5 million in Q2 2023 and bottomed at -$23.9 million in Q2 2025.
• The 5-year median for EBITDA is $55.9 million (2023), against an average of $56.3 million.
• Across the five-year window, EBITDA tumbled 152.07% in 2025 and jumped 95.04% in 2026, its largest moves.
• Year by year, EBITDA stood at $67.9 million in 2022, then slumped by 44.02% to $38.0 million in 2023, then grew by 24.77% to $47.4 million in 2024, then advanced by 14.85% to $54.5 million in 2025, then surged by 38.62% to $75.5 million in 2026.
• Per Business Quant, the three latest TECH EBITDA figures stand at $75.5 million (Q1 2026), $54.5 million (Q4 2025), and $47.7 million (Q3 2025).